{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:49Z","timestamp":1777934569907,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T00:00:00Z","timestamp":1663459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune-related pneumonitis is an uncommon but potentially life-threatening adverse event associated with anti-programmed cell death protein-1 therapy, and has a higher recurrence rate than that of other pneumonitis. Glucocorticoids are the first treatment of choice for patients with immune-related pneumonitis over grade 1. Given the toxicity associated with glucocorticoids, they should be withdrawn gradually as soon as pneumonitis is controlled. However, low-dose glucocorticoids are maintained in some patients to prevent immune-related pneumonitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We report a rare case of a patient with Hodgkin lymphoma who developed grade 2 immune-related pneumonitis, requiring long-term low-dose glucocorticoid maintenance therapy, during which pneumonitis disappeared, and complete response was achieved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>Tislelizumab treatment was stopped tentatively, and the patient was given prednisone at an initiating dose of 1\u2005mg\/kg\/d. The cough symptoms were relieved significantly, and pneumonitis was reduced. The prednisone gradually dwindled, but the immune-related pneumonitis was recurrent, requiring prednisone 10 mg daily maintenance therapy. Subsequently, prednisone and tislelizumab were administered simultaneously, and at present, pneumonitis disappeared and the lesions are in complete remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Low-dose glucocorticoids might play an important role in controlling the recurrence and development of immune-related pneumonitis. The dose and course of glucocorticoid in immune-related pneumonitis patients should be individualized to minimize the toxicity of glucocorticoid.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221127699","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T01:06:21Z","timestamp":1663549581000},"page":"986-991","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune-related pneumonitis requiring low-dose prednisone maintenance in one patient with durable complete response"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9778-9639","authenticated-orcid":false,"given":"Yu","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baozhen","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiepeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanli","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingdi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,9,18]]},"reference":[{"key":"bibr1-10781552221127699","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17140-5"},{"key":"bibr2-10781552221127699","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6"},{"key":"bibr3-10781552221127699","author":"Schneider BJ","journal-title":"J Clin Oncol"},{"key":"bibr4-10781552221127699","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030546"},{"key":"bibr5-10781552221127699","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"bibr6-10781552221127699","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1579"},{"key":"bibr7-10781552221127699","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"bibr8-10781552221127699","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13240"},{"key":"bibr9-10781552221127699","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000840"},{"key":"bibr10-10781552221127699","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000337"},{"key":"bibr11-10781552221127699","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i30.9108"},{"key":"bibr12-10781552221127699","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219872786"},{"key":"bibr13-10781552221127699","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1283"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221127699","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221127699","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221127699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:34Z","timestamp":1777688854000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221127699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,18]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1177\/10781552221127699"],"URL":"https:\/\/doi.org\/10.1177\/10781552221127699","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,18]]}}}